Scienture (SCNX) 10-Q 28 Oct 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 25, 2019
Document And Entity Information
Entity Registrant Name	TRXADE GROUP, INC.
Entity Central Index Key	0001382574
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		38,986,459
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 3,359,288	$ 869,557
Accounts Receivable, net	710,289	433,627
Inventory	63,316	79,966
Prepaid Assets	181,922	82,927
Total Current Assets	4,314,815	1,466,077
Property Plant and Equipment, Net	11,256	15,006
Other Assets
Deposits	21,636	20,531
Right of use leased assets	780,843
Goodwill	725,973	725,973
Total Assets	5,854,523	2,227,587
Current Liabilities
Accounts Payable	397,987	400,544
Accrued Liabilities	151,096	138,323
Current Portion Lease Liabilities	84,050
Short Term Convertible Notes Payable		181,500
Short Term Notes Payable - Related Parties	222,552
Short Term Convertible Notes Payable - Related Parties	100,000	140,000
Total Current Liabilities	955,685	860,367
Long Term Liabilities
Notes Payable - Related Parties	300,000	522,552
Other Long-term Liabilities - Leases	708,289
Total Liabilities	1,963,974	1,382,919
Shareholders' Equity
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of September 30, 2019 and December 31, 2018, respectfully
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 38,636,459 and 33,285,827 shares issued and outstanding, as of September 30, 2019 and December 31, 2018, respectively	386	332
Additional Paid-in Capital	11,790,463	8,955,411
Retained Deficit	(7,900,300)	(8,111,075)
Total Shareholders' Equity	3,890,549	844,668
Total Liabilities and Shareholders' Equity	$ 5,854,523	$ 2,227,587

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Series A Preferred stock, par value	$ 0.00001	$ 0.00001
Series A Preferred stock, shares authorized	10,000,000	10,000,000
Series A Preferred stock, shares issued
Series A Preferred stock, shares outstanding
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	38,636,459	33,285,827
Common stock, shares outstanding	38,636,459	33,285,827

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues	$ 2,311,426	$ 847,471	$ 5,740,361	$ 2,538,082
Cost of Sales	1,000,917	2,345	2,119,894	2,345
Gross Profit	1,310,509	845,126	3,620,467	2,535,737
Operating Expenses
General and Administrative	1,132,656	753,297	3,138,150	2,313,734
Operating Income	177,853	91,829	482,317	222,003
Other Income	25,275	22,500	25,275	22,500
Investment Loss	(162,178)		(250,000)
Loss on Extinguishment of Debt		(7,444)		(7,444)
Interest Expense	(13,385)	(12,636)	(46,817)	(40,028)
Net Income	$ 27,565	$ 94,249	$ 210,775	$ 197,031
Net Income per Common Share - Basic:	$ 0	$ 0	$ 0.01	$ 0.01
Net Income per Common Share -Diluted:	$ 0	$ 0	$ 0.01	$ 0.01
Weighted average Common Shares Outstanding Basic	34,489,969	32,083,629	34,370,522	32,083,629
Weighted average Common Shares Outstanding Diluted	36,286,487	34,737,964	36,167,040	34,732,540

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017		$ 320	$ 7,807,860	$ (8,120,113)	$ (311,933)
Balance, shares at Dec. 31, 2017		31,985,827
Options Expense			37,456		37,456
Net Income				82,269	82,269
Balance at Mar. 31, 2018		$ 320	7,845,316	(8,037,844)	(192,208)
Balance, shares at Mar. 31, 2018		31,985,827
Balance at Dec. 31, 2017		$ 320	7,807,860	(8,120,113)	(311,933)
Balance, shares at Dec. 31, 2017		31,985,827
Warrant Expense
Net Income					197,031
Balance at Sep. 30, 2018		$ 323	8,248,349	(7,923,082)	325,590
Balance, shares at Sep. 30, 2018		32,285,827
Balance at Mar. 31, 2018		$ 320	7,845,316	(8,037,844)	(192,208)
Balance, shares at Mar. 31, 2018		31,985,827
Options Expense			50,616		50,616
Net Income				20,513	20,513
Balance at Jun. 30, 2018		$ 320	7,895,932	(8,017,331)	(121,079)
Balance, shares at Jun. 30, 2018		31,985,827
Options Expense			44,976		44,976
Common Stock Issued for cash		$ 3	299,997		300,000
Common Stock Issued for cash, shares		300,000
Warrants issued for Debt Amendment			7,444		7,444
Net Income				94,249	94,249
Balance at Sep. 30, 2018		$ 323	8,248,349	(7,923,082)	325,590
Balance, shares at Sep. 30, 2018		32,285,827
Balance at Dec. 31, 2018		$ 332	8,955,411	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		33,285,827
Options Expense			35,979		35,979
Common Stock issued for convertible debt and accrued interest		$ 4	211,979		211,983
Common Stock issued for convertible debt and accrued interest, shares		423,996
Warrants Exercised		$ 1	165		166
Warrants Exercised, shares		16,666
Net Income				125,229	125,229
Balance at Mar. 31, 2019		$ 337	9,203,534	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		33,726,459
Balance at Dec. 31, 2018		$ 332	8,955,411	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		33,285,827
Warrant Expense					26,363
Net Income					210,775
Balance at Sep. 30, 2019		$ 386	11,790,463	(7,900,300)	3,890,549
Balance, shares at Sep. 30, 2019		38,636,459
Balance at Mar. 31, 2019		$ 337	9,203,534	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		33,726,459
Options Expense			64,011		64,011
Net Income				57,981	57,981
Balance at Jun. 30, 2019		$ 337	9,267,545	(7,927,865)	1,340,017
Balance, shares at Jun. 30, 2019		33,726,489
Options Expense			41,604		41,604
Common Stock Issued for cash		$ 49	2,454,951		2,455,000
Common Stock Issued for cash, shares		4,910,000
Warrant Expense			26,363		26,363
Net Income				27,565	27,565
Balance at Sep. 30, 2019		$ 386	$ 11,790,463	$ (7,900,300)	$ 3,890,549
Balance, shares at Sep. 30, 2019		38,636,459

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating Activities:
Net Income	$ 210,775	$ 197,031
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation Expense	3,750
Options expense	141,594	133,048
Warrant Expense	26,363
Bad Debt Expense	6,084	2,271
Loss on extinguishment of Debt		7,444
Investment loss	250,000
Amortization of right to use asset	66,598
Amortization of Debt Discount		152
Changes in operating assets and liabilities:
Accounts Receivable	(282,746)	(102,382)
Prepaid Assets and other Current Assets	(100,100)	(70,194)
Inventory	16,650	(13,865)
Other Assets		(20,500)
Lease Liability	(55,102)
Accounts Payable	(2,557)	248
Accrued Liabilities and Other Liabilities	43,256	98,062
Net Cash provided by operating activities	324,565	231,315
Investing Activities:
Purchase of equity method investment	(250,000)
Net cash Used in Investing activities	(250,000)
Financing Activities:
Repayments of Short-Term Convertible Debt - Related Parties	(40,000)	(111,725)
Repayments of Short-Term Promissory Notes		(10,739)
Proceeds from exercise of Warrants	166
Proceeds from Issuance of Common Stock	2,455,000	300,000
Net Cash provided by financing activities	2,415,166	177,536
Net increase in Cash	2,489,731	408,851
Cash at Beginning of the Year	869,557	183,914
Cash at September 30, 2019 and 2018	3,359,288	592,765
Supplemental Cash Flow Information
Cash Paid for Interest	40,705	40,028
Cash Paid for Income Taxes
Non-Cash Transactions
Common Stock Issued for Conversion of Note and Accrued Interest	211,983
ROU assets and operating lease obligations recognized	$ 847,441

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Trxade Group, Inc. (“we”, “our”, “Trxade”, and the “Company”) owns 100% of Trxade, Inc., Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC and Alliance Pharma Solutions, LLC. The merger of Trxade, Inc. and Trxade Group, Inc. occurred in May 2013. Community Specialty Pharmacy was acquired in October 2018. Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on specialty medications. The company operates with an innovative pharmacy model which offers home delivery services to patients thereby providing convenience. Alliance Pharma Solutions, LLC, has developed a same day Pharma delivery software – Delivmeds.com, and invested in SyncHealth MSO, LLC, a managed services organization during January 2019. Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2018 as reported in the Company’s Annual Report on Form 10-K have been omitted. Equity Investments The share of income (loss) of such entities is recorded as a single amount as share in equity income (loss) of investments. Dividends, if any, are recorded as a reduction of the investment. The equity investment was fully impaired at September 30, 2019. Income Per Common Share The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01 Recent Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842 Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-7”), which aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements.

Short-Term Debt and Related Par

Short-Term Debt and Related Parties Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Short-Term Debt and Related Parties Debt	NOTE 2 – SHORT-TERM DEBT AND RELATED PARTIES DEBT Convertible Promissory Note In February 2019, convertible promissory notes issued in 2015 for $181,500 were amended to have a conversion price of $0.50 per share, and the principal and accrued interest totaling $211,983, were then converted into 423,966 common shares. As of September 30, 2019 and December 31, 2018, short-tern convertible notes payable has a balance of $0 and $181,500, respectively, net of $0 unamortized debt discount. Related Party Convertible Promissory Note As of September 30, 2019, the $40,000 in convertible promissory notes due to Mr. Shilpa Patel, a relative of Mr. Prashant Patel, the Company’s President and director, was paid in full. As of September 30, 2019, a $100,000 convertible promissory note was due to Mr. Nitil Patel, the brother of Mr. Prashant Patel, the Company’s President and director. Simple interest of 10% is payable at the maturity date of the note. In July 2019, the note was extended to October 15, 2019, and the modification was not considered substantial. The note was converted in October 2019 into 200,000 shares of common stock. See NOTE 11 – SUBSEQUENT EVENTS. As of September 30, 2019, $122,552 and $100,000 in promissory notes were due to Mr. Prashant Patel and Mr. Suren Ajjarapu, the President and director, and Chief Executive Officer and Chairman, respectively. The notes are due July 1, 2020 and each bear interest at the rate of 6% per annum. The notes were paid in full on October 8, 2019. See NOTE 11 – SUBSEQUENT EVENTS.

Long Term Debt - Related Partie

Long Term Debt - Related Parties	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Long Term Debt - Related Parties	NOTE 3 – LONG TERM DEBT – RELATED PARTIES In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $300,000 promissory note was issued to Nikul Panchal, a non-executive officer of the Company, accruing simple interest at the rate of 10% per annum, payable annually, and having a maturity date in October 2021. In October 2019, $75,000 of the note was converted into 150,000 common shares. See NOTE 11 –SUBSEQUENT EVENTS.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Shareholders' Equity	NOTE 4 – SHAREHOLDERS’ EQUITY In July 2018, under a Private Offer Memorandum, 300,000 shares of common stock were sold for $300,000 in cash. The common stock was sold at $1.00 per share. In connection with this common stock offering, warrants to purchase 161,538 shares of common stock were issued with a strike price of $0.01 and an expiration date of five years. In February 2019, convertible promissory notes issued in 2015 in the amount of $181,500, were amended to include a conversion price of $0.50 per share, and the principal and accrued interest totaling $211,983 was then converted into 423,966 common shares. In February 2019, warrants to purchase 16,666 shares of common stock issued in 2014 with an exercise price of $0.01 per share were exercised for $166 in cash and the Company issued 16,666 common shares. In April and May 2019, options to purchase 505,000 shares of common stock were granted with exercise prices of between $0.41 and $0.44 per share, and a term of 10 years from the grant date. The options vest over a period of four to five years. On July 10, 2019, the Company entered into a securities Purchase Agreement with a certain accredited investor with respect to the private placement of 2,000,000 shares of its common stock at a purchase price of $0.50 per share, for gross proceeds of $1,000,000. This transaction closed on July 30, 2019. On September 1, 2019, the Company granted Flacane Advisors, Inc., a company controlled by Gary Augusta, a member of the Board of Directors of the Company, warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.01 per share. Based on the agreement, warrants to purchase 150,000 shares vest on April 1, 2020 and warrants to purchase 150,000 shares vest on April 1, 2021. The warrants have a term of 5 years. On September 30, 2019, the Company entered into Securities Purchase Agreements with certain accredited investors with respect to the private placement of 2,910,000 shares of common stock at a purchase price of $0.50 per share, for gross proceeds of $1,455,000. Subscribers included Bedford Falls Capital, which is controlled by Gary Augusta, our director (1,000,000 shares); Nitesh Patel, who is the cousin of Prashant Patel, our director and President (40,000 shares); and Shilpa Patel, who is the spouse of Nitesh Patel, the brother of Prashant Patel, our director and President (20,000 shares).

Warrants

Warrants	9 Months Ended
	Sep. 30, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 5 - WARRANTS For the nine-month period ended September 30, 2019, warrants to purchase 16,666 shares of common stock were exercised, 300,000 were granted and none forfeited. See NOTE 4 – SHAREHOLDERS’ EQUITY. The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the warrants granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 217 % Weighted-average risk-free interest rate 2.75 % Expected life of warrants 5 years The total fair value of warrants issued was $269,719. The compensation cost related to the warrants was $26,363 for the nine-months ended September 30, 2019. The Company’s outstanding and exercisable warrants as of September 30, 2019 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2018 2,880,141 $ 0.08 3.74 $ 782,385 Warrants granted 300,000 $ 0.01 - - Warrants forfeited - - - - Warrants exercised (16,666 ) $ 0.01 - - Warrants Outstanding as of September 30, 2019 3,163,475 $ 0.08 3.02 $ 3,574,954

Options

Options	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Options	NOTE 6 – OPTIONS The Company maintains a stock option plan under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plan provides for the grant of up to 2,000,000 shares. All options may be exercised for a period up to four and a half years following the grant date, after which they expire. Options are vested up to 5 years from the grant date. For the nine-month period ended September 30, 2019, options to purchase 505,000 shares of common stock were issued, 25,800 were forfeited and 35,700 expired, due to employee resignations. The Company uses the Black-Sholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 209-250 % Weighted-average risk-free interest rate 2.08-2.55 % Expected life of options 5-7 years Total compensation cost related to stock options was $141,594 and $133,048 for the nine-months ended September 30, 2019 and 2018, respectively. The following table represents stock option activity for the nine-month period ended September 30, 2019: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2018 1,732,846 $ 1.19 6.98 $ - Options Exercisable as of December 31, 2018 1,107,259 $ 0.96 5.91 Options granted 505,000 $ 0.43 - - Options forfeited 25,800 $ 0.92 - - Options expired 35,700 $ 0.60 - - Options Outstanding as of September 30, 2019 2,176,346 $ 0.73 7.01 $ 1,303,547 Options Exercisable as of September 30, 2019 1,204,521 $ 0.89 5.69 $ 537,356

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	NOTE 7 – LEASES The Company elected the practical expedient under ASU 2018-11 “Leases: Targeted Improvements” which allows the Company to apply the transition provision for Topic 842 at the Company’s adoption date instead of at the earliest comparative period presented in the financial statements. Therefore, the Company recognized and measured leases existing at January 1, 2019 but without retrospective application. In addition, the Company elected the optional practical expedient permitted under the transition guidance which allows the Company to carry forward the historical accounting treatment for existing leases upon adoption. No impact was recorded to the beginning retained earnings for Topic 842. The Company has two operating leases for corporate offices. The following table outlines the details: Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 % The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of September 30, 2019 Amounts due within twelve months of September 30 2019 $ 159,538 2020 164,299 2021 169,223 2022 174,320 2023 179,552 Thereafter 259,858 Total minimum lease payments 1,106,790 Less: effect of discounting (314,451 ) Present value of future minimum lease payments 792,339 Less: current obligations under leases 84,050 Long-term lease obligations $ 708,289 For the three-months and nine-months ended September 30, 2019 amortization of assets was $22,658 and $66,598, respectively. For the three-months and nine-months ended September 30, 2019, amortization of liabilities was $18,826 and $55,102, respectively.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	NOTE 8 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Community Specialty and Integra. Nine Months Ended September 30, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Unallocated Total Revenue $ 3,335,050 $ 1,412,449 $ 992,862 $ - $ 5,740,361 Segment Assets $ 1,561,760 $ 315,681 411,161 $ 3,565,921 $ 5,854,523 Segment Profit/Loss $ 1,748,896 $ (75,955 ) $ (122,144 ) $ (1,340,022 ) $ 210,775 The Company had no reportable segments for the nine months ended September 30, 2018. See NOTE 9 – BUSINESS COMBINATION.

Business Combination

Business Combination	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Business Combination	NOTE 9 – BUSINESS COMBINATION On October 15, 2018, the Trxade Group, Inc. (“Company”) entered into and consummated the purchase of 100% of the equity interests of Community Specialty Pharmacy, LLC, a Florida limited liability company, (“CSP”), pursuant to the terms and conditions of the Membership Interest Purchase Agreement, entered into by and among the Company as the buyer, and CSP, and Nikul Panchal, the equity owner of CSP (collectively, the “Seller”). The purchase price for the 100% equity interest in CSP was $300,000 in cash, a promissory note from the Company of $300,000 (see Note 3), and warrants to purchase 405,507 shares of the common stock of the Company which vested on the acquisition date, are exercisable for eight (8) years from the issuance date at a strike price of $0.01 per share, and subject to exercise restrictions which lapse over three (3) years. The Company recorded the acquisition under ASC 805 “Business Combination. All the assets acquired and liabilities assumed are recorded at their corresponding fair values. The excess of the purchase price over the net assets acquired resulted in goodwill of $725,973. The following table is a summary of the allocation of the purchase price of $770,291 consisting of $300,000 in cash, a promissory note from the Company of $300,000, and the fair value of the warrants issued calculated under the Black-Scholes calculation at $170,291. Purchase Price Allocation Purchase Price $ 770,291 Cash (49,728 ) Accounts Receivable (114,899 ) Inventory (76,156 ) Prepaid (3,000 ) Accounts Payable 199,312 Accrued Expenses 153 Goodwill $ 725,973 The accompanying unaudited pro forma statements of operations presents the accounts of Trxade and CSP for the nine- months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 2,538,082 $ 1,985,620 $ 4,523,702 Net Income $ 197,031 $ 97,371 $ 294,402 Net Income per common share – basic $ 0.01 $ 0.01 Net Income per common share - diluted $ 0.01 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,732,540 34,732,540 The accompanying unaudited pro forma statements of operations presents the accounts of Trxade and CSP for the three-months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 847,471 $ 662,503 $ 1,509,974 Net Income $ 94,249 $ 109,556 $ 203,805 Net Income per common share – basic $ 0.00 $ 0.01 Net Income per common share - diluted $ 0.00 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,737,964 34,737,964

Equity Method Investment

Equity Method Investment	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	NOTE 10 – EQUITY METHOD INVESTMENT In January 2019, the Company, through its wholly-owned subsidiary Alliance Pharma Solution, LLC (“Alliance”), entered into a transaction to form SyncHealth MSO, LLC (“SyncHealth”). SyncHealth is owned by PanOptic Health, LLC (“PanOptic”) and Alliance. Alliance contributed $250,000 for the acquisition of a 49% equity interest in SyncHealth and the option to acquire the remaining ownership from PanOptic shareholders. Prior to March 31, 2019, $210,000 was paid with the remaining $40,000 paid in April 2019. Pursuant to the operating agreement, PanOptic owns 70% of SyncHealth and Alliance owns 30%; however, pursuant to the Letter Agreement, PanOptic will transfer to Alliance an additional 6% of SyncHealth’s membership units on May 1, 2019, an additional 6% on August 1, 2019 and an additional 7% on November 1, 2019, and at Alliance’s option, the 51% balance on January 31, 2020, upon transfer of between 2,273,329 and 14,776,638 shares of Company common stock based on 2019 Gross Revenue Quotas. As of September 30, 2019, we have not realized any income from the technology and presently we are in discussions to dissolve this relationship. The remaining investment is impaired and written down to $0. For the three-months and nine-months ended September 30, 2019, the Company recorded its equity share in the losses of SyncHealth amounting to $162,178 and $250,000, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 – SUBSEQUENT EVENT On October 8, 2019, $122,552 and $100,000 in promissory notes due to Mr. Prashant Patel and Mr. Suren Ajjarapu, the President and director, and Chief Executive Officer and Chairman, respectively, were paid in full. The notes were due July 1, 2020. In October 2019, the Company converted $175,000 of principal owed under various outstanding promissory notes into 350,000 shares common stock of the Company at $0.50 per share. On October 23, 2019 (the “ Closing Date Seller Member Assets Closing Shares Milestone Shares APA Shares 1. 240,000 shares upon the placement, by the Company, of 40 in-store wellness kiosks, utilizing the Tele Meds Platform, on or before the first anniversary of the Closing Date; 2. 205,000 shares upon placement, by the Company, of 70 in-store wellness kiosks utilizing the Tele Meds Platform, on or before the first anniversary of the Closing Date; and 3. 205,000 shares upon placement, by the Company, of 100 in-store wellness kiosks utilizing the Tele Meds Platform on or before the first anniversary of the Closing Date. The Asset Purchase Agreement includes a three year non-compete requirement, prohibiting the Seller and the Member from competing against the Assets, customary representations and indemnification obligations, subject to a $25,000 minimal claim amount and certain limitations on liability disclosed in the Asset Purchase Agreement. The Asset Purchase Agreement also requires the Company to fund up to $600,000 in connection with the remote hub installation, marketing and IT, subject to certain milestones set forth in the Asset Purchase Agreement (the “ Funding Obligation

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2018 as reported in the Company’s Annual Report on Form 10-K have been omitted.
Equity Investments	Equity Investments The share of income(loss) of such entities is recorded as a single amount as share in equity income (loss) of investments. Dividends, if any, are recorded as a reduction of the investment. The equity investment was fully impaired at September 30, 2019.
Income Per Common Share	Income Per Common Share The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01
Recent Accounting Pronouncements	Recent Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842 Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-7”), which aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements.

Organization and Basis of Pre_3

Organization and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Warrants and Rights Note Disclosure [Abstract]
Summary of Assumptions Used to Estimate Fair Value of Warrants Granted	The following table summarizes the assumptions used to estimate the fair value of the warrants granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 217 % Weighted-average risk-free interest rate 2.75 % Expected life of warrants 5 years
Schedule of Outstanding and Exercisable Warrants	The Company’s outstanding and exercisable warrants as of September 30, 2019 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2018 2,880,141 $ 0.08 3.74 $ 782,385 Warrants granted 300,000 $ 0.01 - - Warrants forfeited - - - - Warrants exercised (16,666 ) $ 0.01 - - Warrants Outstanding as of September 30, 2019 3,163,475 $ 0.08 3.02 $ 3,574,954

Options (Tables)

Options (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Estimate Fair Value of Stock Options	The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 209-250 % Weighted-average risk-free interest rate 2.08-2.55 % Expected life of options 5-7 years
Schedule of Stock Option Activity	The following table represents stock option activity for the nine-month period ended September 30, 2019: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2018 1,732,846 $ 1.19 6.98 $ - Options Exercisable as of December 31, 2018 1,107,259 $ 0.96 5.91 Options granted 505,000 $ 0.43 - - Options forfeited 25,800 $ 0.92 - - Options expired 35,700 $ 0.60 - - Options Outstanding as of September 30, 2019 2,176,346 $ 0.73 7.01 $ 1,303,547 Options Exercisable as of September 30, 2019 1,204,521 $ 0.89 5.69 $ 537,356

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule of Operating Leases	The following table outlines the details: Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 %
Schedule of Future Minimum Payments for Operating Lease Liabilities	The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of September 30, 2019 Amounts due within twelve months of September 30 2019 $ 159,538 2020 164,299 2021 169,223 2022 174,320 2023 179,552 Thereafter 259,858 Total minimum lease payments 1,106,790 Less: effect of discounting (314,451 ) Present value of future minimum lease payments 792,339 Less: current obligations under leases 84,050 Long-term lease obligations $ 708,289

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of Business Interests Into Reportable Segments	The Company classifies its business interests into reportable segments which are Trxade, Community Specialty and Integra. Nine Months Ended September 30, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Unallocated Total Revenue $ 3,335,050 $ 1,412,449 $ 992,862 $ - $ 5,740,361 Segment Assets $ 1,561,760 $ 315,681 411,161 $ 3,565,921 $ 5,854,523 Segment Profit/Loss $ 1,748,896 $ (75,955 ) $ (122,144 ) $ (1,340,022 ) $ 210,775

Business Combination (Tables)

Business Combination (Tables)	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	Purchase Price Allocation Purchase Price $ 770,291 Cash (49,728 ) Accounts Receivable (114,899 ) Inventory (76,156 ) Prepaid (3,000 ) Accounts Payable 199,312 Accrued Expenses 153 Goodwill $ 725,973
Schedule of Unaudited Pro Forma Statements of Operations	The accompanying unaudited pro forma statements of operations presents the accounts of Trxade and CSP for the nine- months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 2,538,082 $ 1,985,620 $ 4,523,702 Net Income $ 197,031 $ 97,371 $ 294,402 Net Income per common share – basic $ 0.01 $ 0.01 Net Income per common share - diluted $ 0.01 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,732,540 34,732,540 The accompanying unaudited pro forma statements of operations presents the accounts of Trxade and CSP for the three-months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 847,471 $ 662,503 $ 1,509,974 Net Income $ 94,249 $ 109,556 $ 203,805 Net Income per common share – basic $ 0.00 $ 0.01 Net Income per common share - diluted $ 0.00 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,737,964 34,737,964

Organization and Basis of Pre_4

Organization and Basis of Presentation (Details Narrative)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%
Equity investments own percentage, description	If the investments are less than 50% owned and more than 20% owned the entities use the equity method of accounting in accordance with ASC 323-10 Investments - Equity Method and Joint Ventures.

Organization and Basis of Pre_5

Organization and Basis of Presentation - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income	$ 27,565	$ 57,981	$ 125,229	$ 94,249	$ 20,513	$ 82,269	$ 210,775	$ 197,031
Numerator for basic and diluted EPS - income available to common Shareholders	$ 27,565			$ 94,249			$ 210,775	$ 197,031
Denominator for basic EPS - Weighted average shares	34,489,969			32,083,629			34,370,522	32,083,629
Dilutive Effect of Warrants, Options and Convertible Debt	1,796,518			2,654,335			1,796,518	2,648,911
Denominator for diluted EPS - adjusted Weighted average shares and assumed Conversions	36,286,487			34,737,964			36,167,040	34,732,540
Basic and Diluted income per common share	$ 0			$ 0			$ 0.01	$ 0.01

Short-term Debt and Related P_2

Short-term Debt and Related Parties Debt (Details Narrative) - USD ($)	Oct. 08, 2019	Oct. 31, 2019	Jul. 31, 2019	Feb. 28, 2019	Sep. 30, 2019	Dec. 31, 2018
Short-term Debt [Line Items]
Short term convertible notes payable						$ 181,500
Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument conversion price per share		$ 0.50
Debt principal and accrued interest, amount		$ 175,000
Debt instrument conversion shares		350,000
Mr. Prashant Patel [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument maturity date	Jul. 1, 2020
Mr. Suren Ajjarapul [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument maturity date	Jul. 1, 2020
Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Convertible promissory notes				$ 181,500
Debt instrument conversion price per share				$ 0.50
Debt principal and accrued interest, amount				$ 211,983
Debt instrument conversion shares				423,966
Short term convertible notes payable					0	181,500
Debt discount unamortized					0	$ 0
Related Party Convertible Promissory Note [Member] | Mr. Shilpa Patel [Member]
Short-term Debt [Line Items]
Convertible promissory notes					40,000
Related Party Convertible Promissory Note [Member] | Mr. Nitil Patel [Member]
Short-term Debt [Line Items]
Convertible promissory notes					$ 100,000
Interest rate					10.00%
Related Party Convertible Promissory Note [Member] | Mr. Nitil Patel [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument conversion shares		200,000
Related Party Convertible Promissory Note [Member] | Mr. Nitil Patel [Member] | Extended Maturity [Member]
Short-term Debt [Line Items]
Debt instrument maturity date			Oct. 15, 2019
Related Party Convertible Promissory Note [Member] | Mr. Prashant Patel [Member]
Short-term Debt [Line Items]
Convertible promissory notes					$ 122,552
Interest rate					6.00%
Debt instrument maturity date					Jul. 1, 2020
Related Party Convertible Promissory Note [Member] | Mr. Suren Ajjarapul [Member]
Short-term Debt [Line Items]
Convertible promissory notes					$ 100,000
Interest rate					6.00%
Debt instrument maturity date					Jul. 1, 2020

Long Term Debt - Related Part_2

Long Term Debt - Related Parties (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long term debt related party			$ 300,000	$ 522,552
Subsequent Event [Member]
Debt Instrument [Line Items]
Debt instrument conversion amount	$ 175,000
Debt instrument conversion shares	350,000
Related Party Promissory Note [Member] | Community Specialty Pharmacy, LLC [Member] | Nikul Panchal [Member]
Debt Instrument [Line Items]
Proceeds from issuance of promissory note		$ 300,000
Interest rate		10.00%
Debt instrument maturity date		Oct. 31, 2021
Related Party Promissory Note [Member] | Community Specialty Pharmacy, LLC [Member] | Nikul Panchal [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt instrument conversion amount	$ 75,000
Debt instrument conversion shares	150,000

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Sep. 30, 2019	Jul. 10, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jul. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 01, 2019
Class of Stock [Line Items]
Warrants to purchase common stock					16,666
Warrant exercise price					$ 0.01
Number of warrants exercised for cash					$ 166
Number of common shares issued for warrants exercised					16,666
Number of options, granted			505,000	505,000			505,000
Exercise price of options granted							$ 0.43
Option term			10 years	10 years			6 years 11 months 23 days
Proceeds from issuance of common stock							$ 2,455,000	$ 300,000
Gary Augusta [Member] | Vest on April 1, 2020 [Member]
Class of Stock [Line Items]
Warrants to purchase common stock									150,000
Gary Augusta [Member] | Vest on April 1, 2021 [Member]
Class of Stock [Line Items]
Warrants to purchase common stock									150,000
Flacane Advisors, Inc [Member] | Gary Augusta [Member]
Class of Stock [Line Items]
Warrants to purchase common stock									300,000
Warrant exercise price									$ 0.01
Warrants term									5 years
Minimum [Member]
Class of Stock [Line Items]
Exercise price of options granted			$ 0.41	$ 0.41
Option vested period			4 years	4 years
Stock issued during period							2,273,329
Maximum [Member]
Class of Stock [Line Items]
Exercise price of options granted			$ 0.44	$ 0.44
Option vested period			5 years	5 years
Stock issued during period							14,776,638
Convertible Promissory Note [Member]
Class of Stock [Line Items]
Convertible promissory notes					$ 181,500
Debt instrument conversion price per share					$ 0.50
Debt principal and accrued interest, amount					$ 211,983
Debt instrument conversion shares					423,966
Private Offer Memorandum [Member]
Class of Stock [Line Items]
Common stock sold for cash, shares						300,000
Common stock issued for cash						$ 300,000
Sale of stock price per share						$ 1
Warrants to purchase common stock						161,538
Warrant exercise price						$ 0.01
Warrants term						5 years
Securities Purchase Agreement [Member] | Private Placement [Member] | Certain Accredited Investor [Member]
Class of Stock [Line Items]
Stock issued during period	2,910,000	2,000,000
Shares issued price per share	$ 0.50	$ 0.50					$ 0.50
Proceeds from issuance of common stock	$ 1,455,000	$ 1,000,000
Securities Purchase Agreement [Member] | Private Placement [Member] | Gary Augusta [Member]
Class of Stock [Line Items]
Stock issued during period	1,000,000
Securities Purchase Agreement [Member] | Private Placement [Member] | Nitesh Patel [Member]
Class of Stock [Line Items]
Stock issued during period	40,000
Securities Purchase Agreement [Member] | Private Placement [Member] | Shilpa Patel [Member]
Class of Stock [Line Items]
Stock issued during period	20,000

Warrants (Details Narrative)

Warrants (Details Narrative) - Warrant [Member]	9 Months Ended
	Sep. 30, 2019shares
Class of Warrant or Right [Line Items]
Number of warrants exercised	16,666
Number of warrants granted	300,000
Number of warrants forfeited

Warrants - Summary of Assumptio

Warrants - Summary of Assumptions Used to Estimate Fair Value of Warrants Granted (Details)	Sep. 30, 2019
Expected Dividend Yield [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0
Weighted-average Expected Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	2.17
Weighted-average Risk-free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.0275
Expected Life of Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, term	5 years

Warrants - Schedule of Outstand

Warrants - Schedule of Outstanding and Exercisable Warrants (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding Shares, Warrants Outstanding Beginning | shares	2,880,141
Number of Outstanding Shares, Warrants granted | shares	300,000
Number of Outstanding Shares, Warrants forfeited | shares
Number of Outstanding Shares, Warrants exercised | shares	(16,666)
Number of Outstanding Shares, Warrants Outstanding Ending | shares	3,163,475
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 0.08
Weighted Average Exercise Price, Warrants granted | $ / shares	0.01
Weighted Average Exercise Price, Warrants forfeited | $ / shares
Weighted Average Exercise Price, Warrants exercised | $ / shares	0.01
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 0.08
Contractual Life Warrants Outstanding, Beginning	3 years 8 months 26 days
Contractual Life Warrants Outstanding, granted	0 years
Contractual Life Warrants Outstanding, forfeited	0 years
Contractual Life Warrants Outstanding, exercised	0 years
Contractual Life Warrants Outstanding Ending	3 years 7 days
Aggregate Intrinsic Value Outstanding Beginning | $	$ 782,385
Aggregate Intrinsic Value Outstanding Ending | $	$ 3,574,954

Options (Details Narrative)

Options (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
	May 31, 2019	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted	505,000	505,000	505,000
Stock options, forfeited			25,800
Stock options, expired			35,700
Stock options, compensation cost			$ 141,594	$ 133,048
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted			2,000,000
Stock options, description			All options may be exercised for a period up to four and a half years following the grant date, after which they expire.
Stock options, vested period			5 years

Options - Schedule of Estimate

Options - Schedule of Estimate Fair Value of Stock Options (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Weighted-average expected volatility, minimum	209.00%
Weighted-average expected volatility, maximum	250.00%
Weighted-average risk-free interest rate, minimum	2.08%
Weighted-average risk-free interest rate, maximum	2.55%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options		5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options		7 years

Options - Schedule of Stock Opt

Options - Schedule of Stock Option Activity (Details) - USD ($)	1 Months Ended		9 Months Ended
	May 31, 2019	Apr. 30, 2019	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning Balance			1,732,846
Number of Options Exercisable, Beginning Balance			1,107,259
Number of Options, Granted	505,000	505,000	505,000
Number of Options, Forfeited			25,800
Number of Options, Expired			35,700
Number of Options Outstanding, Ending Balance			2,176,346
Number of Options Exercisable, Ending Balance			1,204,521
Weighted Average Exercise Price Outstanding, Beginning Balance			$ 1.19
Weighted Average Exercise Price Exercisable, Beginning Balance			0.96
Weighted Average Exercise Price, Granted			0.43
Weighted Average Exercise Price, Forfeited			0.92
Weighted Average Exercise Price, Expired			0.60
Weighted Average Exercise Price Outstanding, Ending Balance			0.73
Weighted Average Exercise Price Exercisable, Ending Balance			$ 0.89
Contractual Life in Years Outstanding, Beginning Balance	10 years	10 years	6 years 11 months 23 days
Contractual Life in Years Exercisable, Beginning Balance			5 years 10 months 28 days
Contractual Life in Years, Granted			0 years
Contractual Life in Years, Forfeited			0 years
Contractual Life in Years, Expired			0 years
Contractual Life in Years Outstanding, Ending Balance			7 years 4 days
Contractual Life in Years Exercisable, Ending Balance			5 years 8 months 9 days
Intrinsic Value Outstanding, Beginning Balance
Intrinsic Value Exercisable, Beginning Balance
Intrinsic Value Outstanding, Ending Balance			1,303,547
Intrinsic Value Exercisable, Ending Balance			$ 537,356

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)Integer
Leases [Abstract]
Operating leases units | Integer		2
Operating lease amortization of assets	$ 22,658	$ 66,598
Operating lease amortization of liabilities	$ 18,826	$ 55,102

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Initial Recognition of Right to use assets at January 1, 2019	$ 780,843
Lease 1 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	December 2017 to December 2021
Renewal Term	January 2021 to December 2024
Initial Recognition of Right to use assets at January 1, 2019	$ 534,140
Incremental Borrowing Rate	10.00%
Lease 2 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Term	November 2023 to November 2028
Initial Recognition of Right to use assets at January 1, 2019	$ 313,301
Incremental Borrowing Rate	10.00%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments for Operating Lease Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
2019	$ 159,538
2020	164,299
2021	169,223
2022	174,320
2023	179,552
Thereafter	259,858
Total minimum lease payments	1,106,790
Less: effect of discounting	(314,451)
Present value of future minimum lease payments	792,339
Less: current obligations under leases	84,050
Long-term lease obligations	$ 708,289

Segment Reporting - Schedule of

Segment Reporting - Schedule of Business Interests Into Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 2,311,426	$ 847,471	$ 5,740,361	$ 2,538,082
Segment Assets	5,854,523		5,854,523		$ 2,227,587
Segment Profit/Loss			210,775
Trxade, Inc. [Member]
Segment Reporting Information [Line Items]
Revenue			3,335,050
Segment Assets	1,561,760		1,561,760
Segment Profit/Loss			1,748,896
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			1,412,449
Segment Assets	315,681		315,681
Segment Profit/Loss			(75,955)
Integra Pharma, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			992,862
Segment Assets	411,161		411,161
Segment Profit/Loss			(122,144)
Unallocated [Member]
Segment Reporting Information [Line Items]
Revenue
Segment Assets	$ 3,565,921		3,565,921
Segment Profit/Loss			$ (1,340,022)

Business Combination (Details N

Business Combination (Details Narrative) - USD ($)	Oct. 15, 2018	Sep. 30, 2019	Feb. 28, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Equity method investment ownership percentage		100.00%
Warrants to purchase common stock			16,666
Warrant strike price			$ 0.01
Goodwill		$ 725,973		$ 725,973
Community Specialty Pharmacy, LLC [Member]
Business Acquisition [Line Items]
Equity method investment ownership percentage	100.00%
Purchase price, cash	$ 300,000
Promissory note issued	$ 300,000
Warrants to purchase common stock	405,507
Warrant term	8 years
Warrant strike price	$ 0.01
Exercise restrictions lapse period	3 years
Goodwill	$ 725,973
Total purchase price	770,291
Fair value of warrants issued	$ 170,291

Business Combination - Schedule

Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Oct. 15, 2018	Sep. 30, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill		$ 725,973	$ 725,973
Community Specialty Pharmacy, LLC [Member]
Business Acquisition [Line Items]
Purchase Price	$ 770,291
Cash	(49,728)
Accounts Receivable	(114,899)
Inventory	(76,156)
Prepaid	(3,000)
Accounts Payable	199,312
Accrued Expenses	153
Goodwill	$ 725,973

Business Combination - Schedu_2

Business Combination - Schedule of Unaudited Pro Forma Statements of Operations (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Business Acquisition [Line Items]
Revenue	$ 1,509,974	$ 4,523,702
Net Income	$ 203,805	$ 294,402
Net Income per common share - basic	$ 0.01	$ 0.01
Net Income per common share - diluted	$ 0.01	$ 0.01
Weighted average common shares - basic	32,083,629	32,083,629
Weighted average common shares - diluted	34,737,964	34,732,540
Trxade [Member]
Business Acquisition [Line Items]
Revenue	$ 847,471	$ 2,538,082
Net Income	$ 94,249	$ 197,031
Net Income per common share - basic	$ 0	$ 0.01
Net Income per common share - diluted	$ 0	$ 0.01
Weighted average common shares - basic	32,083,629	32,083,629
Weighted average common shares - diluted	34,737,964	34,732,540
Community Specialty Pharmacy, LLC [Member]
Business Acquisition [Line Items]
Revenue	$ 662,503	$ 1,985,620
Net Income	$ 109,556	$ 97,371

Equity Method Investment (Detai

Equity Method Investment (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2019	Jan. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Jan. 31, 2020	Nov. 01, 2019	Aug. 01, 2019	May 01, 2019
Schedule of Equity Method Investments [Line Items]
Payment to acquire equity interest					$ 250,000
Equity method investment ownership percentage			100.00%		100.00%
Equity method investment loss			$ 162,178		$ 250,000
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period					2,273,329
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period					14,776,638
SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage									6.00%	6.00%
SyncHealth MSO, LLC [Member] | Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage								7.00%
Alliance Pharma Solution, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Payment to acquire equity interest	$ 40,000	$ 250,000		$ 210,000
Equity method investment ownership percentage		49.00%
Equity method investment			$ 0		$ 0
Alliance Pharma Solution, LLC [Member] | Technology [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment loss
Alliance Pharma Solution, LLC [Member] | SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage		30.00%
PanOptic Health, LLC [Member] | SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage		70.00%
SyncHealth MSO, LLC [Member] | Forecast [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage							51.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 23, 2019USD ($)Integershares	Oct. 08, 2019USD ($)	Oct. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)
Subsequent Event [Line Items]
Repayments of related party debt | $				$ 40,000	$ 111,725
Maximum [Member]
Subsequent Event [Line Items]
Shares issued during the period				14,776,638
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument conversion amount | $			$ 175,000
Debt instrument conversion shares			350,000
Debt instrument conversion price per share | $ / shares			$ 0.50
Subsequent Event [Member] | Mr. Prashant Patel [Member]
Subsequent Event [Line Items]
Repayments of related party debt | $		$ 122,552
Debt instrument maturity date		Jul. 1, 2020
Subsequent Event [Member] | Mr. Suren Ajjarapu [Member]
Subsequent Event [Line Items]
Repayments of related party debt | $		$ 100,000
Debt instrument maturity date		Jul. 1, 2020
Subsequent Event [Member] | Bonum Health, LLC [Member]
Subsequent Event [Line Items]
Number of restricted stock	250,000
Subsequent Event [Member] | Bonum Health, LLC [Member] | Asset Purchase Agreement [Member]
Subsequent Event [Line Items]
Agreement non-compete requirement term	3 years
Minimal claim amount | $	$ 25,000
Subsequent Event [Member] | Bonum Health, LLC [Member] | Maximum [Member] | Asset Purchase Agreement [Member]
Subsequent Event [Line Items]
Amount for installation and milestone payments | $	$ 600,000
Subsequent Event [Member] | Bonum Health, LLC [Member] | APA Shares [Member] | 40 In-Store Wellness Kiosks [Member]
Subsequent Event [Line Items]
Shares issued during the period	240,000
Number of in-store wellness kiosks | Integer	40
Subsequent Event [Member] | Bonum Health, LLC [Member] | APA Shares [Member] | 70 In-Store Wellness Kiosks [Member]
Subsequent Event [Line Items]
Shares issued during the period	205,000
Number of in-store wellness kiosks | Integer	70
Subsequent Event [Member] | Bonum Health, LLC [Member] | APA Shares [Member] | 100 In-Store Wellness Kiosks [Member]
Subsequent Event [Line Items]
Shares issued during the period	205,000
Number of in-store wellness kiosks | Integer	100
Subsequent Event [Member] | Bonum Health, LLC [Member] | APA Shares [Member] | Maximum [Member]
Subsequent Event [Line Items]
Number of restricted stock	650,000